Supriya Lifescience Q3 FY26 Results Show 11% Growth

Supriya Lifescience reported Q3 FY26 revenue of INR206 crores with 11% YoY growth, maintaining strong EBITDA margins at 34.9% and PAT margins at 24.1%.

Supriya Lifescience Q3 FY26 Results Show Growth

Supriya Lifescience reports 11% YoY revenue growth to INR 2,064 Mn in Q3 FY26, with EBITDA up 9% to INR 720.8 Mn and PAT rising 6% to INR 496.8 Mn despite margin compression.

Supriya Lifescience Reports 20% Revenue Growth in Q2 FY26, Back on Track After Q1 Disruption

Supriya Lifescience achieved INR 200 crores revenue in Q2 FY26, marking 20% year-on-year and 38% sequential growth, with EBITDA at INR 73 crores and 36% margin. The company maintains its 20% annual revenue growth guidance and INR 1,000 crore revenue target by FY27, supported by new product launches, backward integration at 79%, and upcoming Ambernath facility commercialization from Q4 FY26.

Supriya Lifescience Reports Quarterly Financial Results for September 2025

Supriya Lifescience Limited announced its unaudited financial results for the quarter and half year ended September 30, 2025. The company reported total revenue from operations of ₹2,794.40 million for the quarter, compared to ₹2,463.50 million in the previous quarter. Net profit for the quarter was ₹504.27 million, up from ₹461.49 million in the prior quarter. For the half year period, total revenue reached ₹5,257.90 million with net profit of ₹965.76 million. The company's cash and cash equivalents stood at ₹992.68 million as of September 30, 2025. The Board of Directors approved these results during their meeting held on November 12, 2025. The results were reviewed by the Audit Committee and received a clean review report from the statutory auditors.

Supriya Lifescience Reports Strong Q2 Growth with Revenue Up 20% Year-on-Year

Supriya Lifescience delivered robust quarterly performance with revenue rising to 1.99 billion rupees from 1.66 billion rupees year-on-year. Net profit increased to 504 million rupees compared to 462 million rupees in the same period last year. EBITDA grew to 726 million rupees from 647 million rupees year-on-year, though EBITDA margin compressed to 36.34% from 39% in the previous year.